^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CD19 CAR T cells
i
Other names: CD19 CAR T cells, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T Cells, CD19R(EQ)28zeta/EGFRt+ Naive and Memory T Cells, CD19R(EQ)28zetaEGFRt+ Tn/mem Cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
City of Hope, National Cancer Institute
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
9d
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
Trial completion date • Trial primary completion date
|
Calquence (acalabrutinib) • CD19 CAR T cells
2ms
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov)
P1, N=37, Active, not recruiting, City of Hope Medical Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
Trial completion date • Trial primary completion date
|
CD19 positive
|
cyclophosphamide • etoposide IV • fludarabine IV • Belrapzo (bendamustine RTD) • CD19 CAR T cells
7ms
Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=51, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Mar 2026
Trial completion date • Trial primary completion date
|
CD19 CAR T cells
10ms
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov)
P1, N=37, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Sep 2025 | Trial primary completion date: Dec 2024 --> Sep 2025
Trial completion date • Trial primary completion date
|
CD19 positive
|
cyclophosphamide • etoposide IV • fludarabine IV • Belrapzo (bendamustine RTD) • CD19 CAR T cells
12ms
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Sep 2025 | Trial primary completion date: Dec 2024 --> Sep 2025
Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Immune cell
|
Calquence (acalabrutinib) • CD19 CAR T cells
1year
Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=71, Active, not recruiting, City of Hope Medical Center | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
Trial completion date • Trial primary completion date
|
CD19 positive
|
CD19 CAR T cells
1year
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024
Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Immune cell
|
Calquence (acalabrutinib) • CD19 CAR T cells
over1year
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=24, Recruiting, City of Hope Medical Center | Trial completion date: Aug 2025 --> Dec 2026 | Trial primary completion date: Aug 2025 --> Dec 2026
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
Erbitux (cetuximab) • cyclophosphamide • fludarabine IV • CD19 CAR T cells
over1year
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=24, Recruiting, City of Hope Medical Center
New P1 trial • CAR T-Cell Therapy
|
Erbitux (cetuximab) • cyclophosphamide • fludarabine IV • CD19 CAR T cells
almost2years
Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=51, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date
|
CD28 (CD28 Molecule)
|
CD28 expression
|
CD19 CAR T cells
almost2years
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov)
P1, N=37, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date
|
CD19 positive
|
cyclophosphamide • etoposide IV • fludarabine IV • Belrapzo (bendamustine RTD) • CD19 CAR T cells
2years
Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=71, Active, not recruiting, City of Hope Medical Center | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
Trial completion date • Trial primary completion date
|
CD19 positive
|
CD19 CAR T cells
Share via
